OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
TEAD Inhibition Overcomes YAP1/TAZ-Driven Primary and Acquired Resistance to KRASG12C Inhibitors
A. Cole Edwards, Clint A. Stalnecker, Alexis Jean Morales, et al.
Cancer Research (2023) Vol. 83, Iss. 24, pp. 4112-4129
Open Access | Times Cited: 30
A. Cole Edwards, Clint A. Stalnecker, Alexis Jean Morales, et al.
Cancer Research (2023) Vol. 83, Iss. 24, pp. 4112-4129
Open Access | Times Cited: 30
Showing 1-25 of 30 citing articles:
Targeting KRAS in cancer
Anupriya Singhal, Bob T. Li, Eileen M. O’Reilly
Nature Medicine (2024) Vol. 30, Iss. 4, pp. 969-983
Closed Access | Times Cited: 67
Anupriya Singhal, Bob T. Li, Eileen M. O’Reilly
Nature Medicine (2024) Vol. 30, Iss. 4, pp. 969-983
Closed Access | Times Cited: 67
Genome-Wide CRISPR Screens Identify Multiple Synthetic Lethal Targets That Enhance KRASG12C Inhibitor Efficacy
Suman Mukhopadhyay, Hsin‐Yi Huang, Ziyan Lin, et al.
Cancer Research (2023) Vol. 83, Iss. 24, pp. 4095-4111
Open Access | Times Cited: 42
Suman Mukhopadhyay, Hsin‐Yi Huang, Ziyan Lin, et al.
Cancer Research (2023) Vol. 83, Iss. 24, pp. 4095-4111
Open Access | Times Cited: 42
Direct and selective pharmacological disruption of the YAP–TEAD interface by IAG933 inhibits Hippo-dependent and RAS–MAPK-altered cancers
Emilie A. Chapeau, Laurent Sansregret, Giorgio Giacomo Galli, et al.
Nature Cancer (2024) Vol. 5, Iss. 7, pp. 1102-1120
Open Access | Times Cited: 33
Emilie A. Chapeau, Laurent Sansregret, Giorgio Giacomo Galli, et al.
Nature Cancer (2024) Vol. 5, Iss. 7, pp. 1102-1120
Open Access | Times Cited: 33
Determining the ERK-regulated phosphoproteome driving KRAS-mutant cancer
Jennifer E. Klomp, J. Nathaniel Diehl, Jeffrey A. Klomp, et al.
Science (2024) Vol. 384, Iss. 6700
Open Access | Times Cited: 20
Jennifer E. Klomp, J. Nathaniel Diehl, Jeffrey A. Klomp, et al.
Science (2024) Vol. 384, Iss. 6700
Open Access | Times Cited: 20
The Extracellular Niche and Tumor Microenvironment Enhance KRAS Inhibitor Efficacy in Pancreatic Cancer
Vishnu Kumarasamy, Jianxin Wang, Costakis Frangou, et al.
Cancer Research (2024) Vol. 84, Iss. 7, pp. 1115-1132
Open Access | Times Cited: 14
Vishnu Kumarasamy, Jianxin Wang, Costakis Frangou, et al.
Cancer Research (2024) Vol. 84, Iss. 7, pp. 1115-1132
Open Access | Times Cited: 14
Hippo Signaling at the Hallmarks of Cancer and Drug Resistance
Ramesh Kumar, Wanjin Hong
Cells (2024) Vol. 13, Iss. 7, pp. 564-564
Open Access | Times Cited: 12
Ramesh Kumar, Wanjin Hong
Cells (2024) Vol. 13, Iss. 7, pp. 564-564
Open Access | Times Cited: 12
A Classical Epithelial State Drives Acute Resistance to KRAS Inhibition in Pancreatic Cancer
Anupriya Singhal, Hannah C. Styers, Jonathan Rub, et al.
Cancer Discovery (2024) Vol. 14, Iss. 11, pp. 2122-2134
Closed Access | Times Cited: 9
Anupriya Singhal, Hannah C. Styers, Jonathan Rub, et al.
Cancer Discovery (2024) Vol. 14, Iss. 11, pp. 2122-2134
Closed Access | Times Cited: 9
KRAS inhibitors: resistance drivers and combinatorial strategies
Tamara Isermann, Christine Sers, Channing J. Der, et al.
Trends in cancer (2024)
Open Access | Times Cited: 6
Tamara Isermann, Christine Sers, Channing J. Der, et al.
Trends in cancer (2024)
Open Access | Times Cited: 6
Discovery of YAP1/TAZ pathway inhibitors through phenotypic screening with potent anti-tumor activity via blockade of Rho-GTPase signaling
Keith Graham, Philip Lienau, Benjamin Bader, et al.
Cell chemical biology (2024) Vol. 31, Iss. 7, pp. 1247-1263.e16
Closed Access | Times Cited: 5
Keith Graham, Philip Lienau, Benjamin Bader, et al.
Cell chemical biology (2024) Vol. 31, Iss. 7, pp. 1247-1263.e16
Closed Access | Times Cited: 5
MARK2/MARK3 Kinases Are Catalytic Codependencies of YAP/TAZ in Human Cancer
Olaf Klingbeil, Damianos Skopelitis, Claudia Tonelli, et al.
Cancer Discovery (2024) Vol. 14, Iss. 12, pp. 2471-2488
Open Access | Times Cited: 5
Olaf Klingbeil, Damianos Skopelitis, Claudia Tonelli, et al.
Cancer Discovery (2024) Vol. 14, Iss. 12, pp. 2471-2488
Open Access | Times Cited: 5
Zehao Pan, Yuxian Qian, Yajing Wang, et al.
Cancer Science (2025)
Open Access
Inhibitors of oncogenic Kras specifically prime CTLA4 blockade to transcriptionally reprogram Tregs and overcome resistance to suppress pancreas cancer
Krishnan K. Mahadevan, Antonio Maldonado, Bingrui Li, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2025)
Closed Access
Krishnan K. Mahadevan, Antonio Maldonado, Bingrui Li, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2025)
Closed Access
Navigating Glioma Complexity: The Role of Abnormal Signaling Pathways in Shaping Future Therapies
Qiang Chen, Jin Jin, Pian Li, et al.
Biomedicines (2025) Vol. 13, Iss. 3, pp. 759-759
Open Access
Qiang Chen, Jin Jin, Pian Li, et al.
Biomedicines (2025) Vol. 13, Iss. 3, pp. 759-759
Open Access
The role of the Hippo/YAP pathway in the physiological activities and lesions of lens epithelial cells
Shumei Tan, Xiaodan Jiang, Ziyuan Liu, et al.
Frontiers in Cell and Developmental Biology (2025) Vol. 13
Open Access
Shumei Tan, Xiaodan Jiang, Ziyuan Liu, et al.
Frontiers in Cell and Developmental Biology (2025) Vol. 13
Open Access
PRMT5 inhibitors: Therapeutic potential in pancreatic cancer
Carolin Schneider, Valentina Spielmann, Christian Braun, et al.
Translational Oncology (2025) Vol. 55, pp. 102366-102366
Closed Access
Carolin Schneider, Valentina Spielmann, Christian Braun, et al.
Translational Oncology (2025) Vol. 55, pp. 102366-102366
Closed Access
Identification of a Gene Signature That Predicts Dependence upon YAP/TAZ-TEAD
Ryan Kanai, Emily Norton, Patrick Stern, et al.
Cancers (2024) Vol. 16, Iss. 5, pp. 852-852
Open Access | Times Cited: 3
Ryan Kanai, Emily Norton, Patrick Stern, et al.
Cancers (2024) Vol. 16, Iss. 5, pp. 852-852
Open Access | Times Cited: 3
Epithelial-mesenchymal transition status is a remarkable biomarker for the combination treatment with avutometinib and defactinib in KRAS-mutated non-small cell lung cancer
Akihiro Yoshimura, Mano Horinaka, Takeshi Yaoi, et al.
British Journal of Cancer (2024) Vol. 131, Iss. 2, pp. 361-371
Closed Access | Times Cited: 3
Akihiro Yoshimura, Mano Horinaka, Takeshi Yaoi, et al.
British Journal of Cancer (2024) Vol. 131, Iss. 2, pp. 361-371
Closed Access | Times Cited: 3
An improved TEAD dominant-negative protein inhibitor to study Hippo YAP1/TAZ-dependent transcription.
Briana Branch, Yao Yuan, Mariastella Cascone, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 1
Briana Branch, Yao Yuan, Mariastella Cascone, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 1
Gastric Adenocarcinomas with CDX2 Induction Show Higher Frequency of TP53 and KMT2B Mutations and MYC Amplifications but Similar Survival Compared with Cancers with No CDX2 Induction
Ioannis A. Voutsadakis
Journal of Clinical Medicine (2024) Vol. 13, Iss. 24, pp. 7635-7635
Open Access | Times Cited: 1
Ioannis A. Voutsadakis
Journal of Clinical Medicine (2024) Vol. 13, Iss. 24, pp. 7635-7635
Open Access | Times Cited: 1
The Hippo pathway: organ size control and beyond
Pengfei Guo, Sicheng Wan, Kun‐Liang Guan
Pharmacological Reviews (2024) Vol. 77, Iss. 2, pp. 100031-100031
Closed Access | Times Cited: 1
Pengfei Guo, Sicheng Wan, Kun‐Liang Guan
Pharmacological Reviews (2024) Vol. 77, Iss. 2, pp. 100031-100031
Closed Access | Times Cited: 1
Direct YAP/TAZ–TEAD inhibitor paves the way toward realizing cancer mechanomedicine
Kostas A. Papavassiliou, Antonios N. Gargalionis, Athanasios G. Papavassiliou
Pharmacological Research (2024) Vol. 206, pp. 107287-107287
Open Access
Kostas A. Papavassiliou, Antonios N. Gargalionis, Athanasios G. Papavassiliou
Pharmacological Research (2024) Vol. 206, pp. 107287-107287
Open Access
Reporter-based screening identifies RAS-RAF stabilizing mutations as drivers of resistance to broad-spectrum RAS inhibition in colorectal cancer
Oleksandra Aust, Eric Blanc, Mareen Lüthen, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Closed Access
Oleksandra Aust, Eric Blanc, Mareen Lüthen, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Closed Access
Transient proliferation by reversible YAP-mediated increase of the cyclin D1/p27 ratio
Katherine R. Ferrick, Yilin Fan, Nalin Ratnayeke, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Katherine R. Ferrick, Yilin Fan, Nalin Ratnayeke, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Paralog Co-Targeting Identifies Selective Genetic Redundancies across Cancer Types
Gregory Gauthier-Coles, Jason M. Sheltzer
Cancer Discovery (2024) Vol. 14, Iss. 12, pp. 2312-2314
Closed Access
Gregory Gauthier-Coles, Jason M. Sheltzer
Cancer Discovery (2024) Vol. 14, Iss. 12, pp. 2312-2314
Closed Access
Suite of Biochemical and Cell-Based Assays for the Characterization of Kirsten Rat Sarcoma (KRAS) Inhibitors and Degraders
Medhanie Kidane, Rene M. Hoffman, Jennifer K. Wolfe-Demarco, et al.
ACS Pharmacology & Translational Science (2024) Vol. 7, Iss. 12, pp. 3921-3934
Open Access
Medhanie Kidane, Rene M. Hoffman, Jennifer K. Wolfe-Demarco, et al.
ACS Pharmacology & Translational Science (2024) Vol. 7, Iss. 12, pp. 3921-3934
Open Access
